Mer­ck steps in­to NASH space with ear­ly da­ta for its GLP-1/glucagon re­cep­tor co-ag­o­nist

Mer­ck is teas­ing da­ta for efinopeg­du­tide, a GLP-1/glucagon re­cep­tor co-ag­o­nist, in non­al­co­holic steato­hep­ati­tis (NASH) and how it com­pares to No­vo Nordisk’s semaglu­tide, with plans to share more de­tailed da­ta from the study at the Eu­ro­pean As­so­ci­a­tion for the Study of the Liv­er’s an­nu­al meet­ing lat­er this month.

Mer­ck plans to use da­ta from efinopeg­du­tide’s Phase IIa tri­al in adult pa­tients with non­al­co­holic fat­ty liv­er dis­ease to in­form a Phase IIb study set to be­gin lat­er this month in NASH, a more se­vere form of the dis­ease, ac­cord­ing to Mer­ck. The FDA re­cent­ly grant­ed the drug, which is al­so be­ing eval­u­at­ed as a treat­ment for obe­si­ty and di­a­betes, a fast track des­ig­na­tion in NASH.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER